SG-3-00802

SG-3-00802 is a **microbiome-derived peptide** immuno-oncology candidate developed by **Second Genome** for cancer treatment, particularly to overcome resistance to **anti-programmed death protein 1 therapy**. The peptide acts as a **C-X-C motif chemokine receptor 3 modulator**, enhancing **CXCR3** signaling in the presence of the endogenous ligand **CXCL11**, with reported **CXCR3-dependent** in vivo activity. In preclinical models, SG-3-00802 showed **single-agent antitumor activity**, induced **CXCL10**, and improved antitumor responses when combined with anti-programmed death protein 1 therapy, supporting its positioning as a **microbiome-based cancer immunotherapy** intended to reverse immune checkpoint inhibitor resistance.